Insight Molecular Diagnostics Inc. (IMDX) Stock Overview
Explore Insight Molecular Diagnostics Inc.’s financial performance, market position, analyst ratings, and future outlook.
Insight Molecular Diagnostics Inc. (IMDX)
Key Financials
Key Financials
Market Cap
161.5M
P/E Ratio
-3.33
EPS (TTM)
$-1.19
ROE
3.81%
IMDX Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Insight Molecular Diagnostics Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of IMDX on the NASDAQ shows an RSI of 50.62, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $8.91 for the NASDAQ listing.
Key metrics behind Insight Molecular Diagnostics Inc.'s NASDAQ-traded stock include a P/E ratio of -3.33 and a market capitalization of 161.5M. Combined with our AI analysis, these give both institutional and retail investors a clear view of IMDX on the NASDAQ.